Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
285.60
-4.14 (-1.43%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Ligand Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 290.54 | 268.09 | 167.13 | 131.31 | 196.25 | 241.54 | |
Revenue Growth | 54.89% | 60.40% | 27.28% | -33.09% | -18.75% | 47.68% |
Cost of Revenue | 54.63 | 95.73 | 32.5 | 35.05 | 88.91 | 94.28 |
Gross Profit | 235.92 | 172.36 | 134.63 | 96.27 | 107.34 | 147.26 |
Selling, General & Admin | 103.43 | 92.45 | 78.65 | 52.79 | 70.06 | 46.79 |
Amortization of Goodwill & Intangibles | 32.39 | 32.71 | 32.96 | 33.65 | 34.24 | 34.22 |
Operating Expenses | 135.82 | 125.16 | 111.61 | 86.44 | 104.3 | 81.01 |
Operating Income | 100.1 | 47.2 | 23.02 | 9.82 | 3.04 | 66.25 |
Interest Expense | -6.19 | -4.72 | -3.04 | -0.66 | -1.8 | -19.62 |
Interest & Investment Income | 24.22 | 13.66 | 8.06 | 7.71 | 2.05 | 0.89 |
Earnings From Equity Investments | 77.17 | 90.67 | -48.6 | -1.8 | - | - |
Other Non Operating Income (Expenses) | 3.38 | -0.09 | -21.37 | 0.1 | -0.01 | -0.35 |
EBT Excluding Unusual Items | 198.68 | 146.72 | -41.93 | 15.17 | 3.28 | 47.17 |
Gain (Loss) on Sale of Investments | 45.48 | 18.43 | 75.02 | 46.37 | 28.54 | -5.26 |
Gain (Loss) on Sale of Assets | - | - | - | 2.12 | - | - |
Asset Writedown | -6.2 | -6.2 | -30.57 | - | - | - |
Other Unusual Items | - | - | - | - | 4.19 | 30.3 |
Pretax Income | 237.96 | 158.96 | 2.52 | 63.66 | 36.01 | 72.21 |
Income Tax Expense | 40.74 | 34.51 | 6.55 | 9.84 | 41.23 | -4.15 |
Earnings From Continuing Operations | 197.22 | 124.45 | -4.03 | 53.82 | -5.22 | 76.35 |
Earnings From Discontinued Operations | - | - | - | -1.67 | -28.14 | -19.22 |
Net Income to Company | 197.22 | 124.45 | -4.03 | 52.15 | -33.36 | 57.14 |
Net Income | 197.22 | 124.45 | -4.03 | 52.15 | -33.36 | 57.14 |
Net Income to Common | 197.22 | 124.45 | -4.03 | 52.15 | -33.36 | 57.14 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 20 | 19 | 18 | 17 | 17 | 17 |
Shares Outstanding (Diluted) | 21 | 20 | 18 | 18 | 17 | 17 |
Shares Change | 12.96% | 10.96% | 3.00% | 5.27% | -2.19% | 2.50% |
EPS (Basic) | 10.01 | 6.44 | -0.22 | 3.02 | -1.98 | 3.44 |
EPS (Diluted) | 9.19 | 6.13 | -0.22 | 2.94 | -1.98 | 3.32 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 131.44 | 48.91 | 95.23 | 46.06 | 125.5 | 70.04 |
Free Cash Flow Per Share | 6.13 | 2.41 | 5.21 | 2.59 | 7.44 | 4.06 |
Gross Margin | 81.20% | 64.29% | 80.55% | 73.31% | 54.70% | 60.97% |
Operating Margin | 34.45% | 17.61% | 13.77% | 7.48% | 1.55% | 27.43% |
Profit Margin | 67.88% | 46.42% | -2.41% | 39.72% | -17.00% | 23.66% |
Free Cash Flow Margin | 45.24% | 18.24% | 56.98% | 35.07% | 63.95% | 29.00% |
EBITDA | 133.01 | 80.97 | 58.26 | 46.34 | 41.35 | 117.2 |
EBITDA Margin | 45.78% | 30.20% | 34.86% | 35.29% | 21.07% | 48.52% |
D&A For EBITDA | 32.91 | 33.78 | 35.24 | 36.52 | 38.32 | 50.95 |
EBIT | 100.1 | 47.2 | 23.02 | 9.82 | 3.04 | 66.25 |
EBIT Margin | 34.45% | 17.61% | 13.77% | 7.48% | 1.55% | 27.43% |
Effective Tax Rate | 17.12% | 21.71% | 260.13% | 15.46% | 114.49% | - |
Revenue as Reported | 290.54 | 268.09 | 167.13 | 131.31 | 196.25 | 241.54 |